Hoosiers Work for Health

11/18/2025

Indiana employers have tools to hold PBMs accountable and reduce costs. State Rep. Julie McQuire outlines how audits, transparency and legislative action can protect businesses and employees from inflated drug pricing.

Indiana employers have powerful tools at their disposal to fight back, and my colleagues and I have worked hard to pass laws to hold these entities accountable, increase transparency and reduce costs.

11/14/2025

America can either cede the future of biotechnology to our adversaries or summon the vision and resolve to lead it.

10/29/2025

“Indiana is a thriving hub for biotech innovation already.” – Senator Jim Banks, Oct. 29, 2025

We couldn’t agree more. Indiana’s life sciences industry drives discovery in cancer research, regenerative medicine and so much more. With over 3,200 companies, 70,000 Hoosier jobs bringing in $7.4 billion in payroll and over $1.6 billion dollars in research funding annually, Indiana is proud to be a national leader in biotechnology innovation.

Senator Banks’ focus on strengthening FDA processes, ensuring fair inspections abroad, and protecting American intellectual property is critical to supporting future innovation and investment in our state.

09/11/2025

The U.S. can cut drug costs without killing innovation. MFN is a quick fix with big risks like shortages, fewer cures and reduced access. Let’s choose competition and smart reform through strong policy and trade talks instead.

Three months have passed since President Trump signed an executive order on “Delivering Most Favored Nation [MFN] Pricing to American Patients,” which requires that pharma reduce

09/04/2025

Most Favored Nation (MFN) style drug pricing is not innovation friendly. Forcing U.S. pharmaceutical companies to match Europe's low prices risks slower breakthroughs.

Republicans aren’t known for raising hell about prescription drug prices and fighting to keep them as low as possible for consumers. Call it a strength of

09/02/2025

It would be catastrophic on multiple levels if we ceded innovative superiority to our international competitors.

09/02/2025

"It would be catastrophic on multiple levels if we ceded innovative superiority to our international competitors. Americans would not have the same access to cutting-edge medical treatments if they are developed overseas instead of here, and the research-driven economic growth that has generated jobs nationally and here in Indiana would be significantly trimmed back."
- We Work For Health Executive Director Dan Leonard

It would be catastrophic on multiple levels if we ceded innovative superiority to our international competitors.

08/13/2025

Price controls abroad often backfire. The U.S. model, driven by competition, can mean cheaper prescriptions and continued innovation. National Review explains why other countries should take notes and why the U.S. adopting a Most Favored Nation policy would set us back.

Not vice versa.

08/13/2025

China is now enrolling patients for clinical trials at twice the pace of the U.S., a clear sign it’s narrowing the gap in global biopharma innovation. The race is heating up, and China is catching up fast.

Chinese biotech's advance has been as ferocious as the nation's breakthrough efforts in AI and EVs, eclipsing the EU and catching up to the US

07/01/2025

Thanks to the Bayh-Dole Act, universities like Purdue, Indiana University and Notre Dame are driving innovation in areas like life sciences and advanced manufacturing. The result is more local investment, stronger communities and an economy that benefits from the ideas born in Indiana and built in Indiana.

Universities play a pivotal role in America’s technology economy, serving as a crucial source of research, inventions, patents, start-up technology companies, and regional economic and employment growth. The Bayh-Dole Act has played an instrumental role in spurring academic technology transfer act...

07/01/2025

New study shows the U.S. pharmaceutical industry powered over 65 million union labor hours and $2.6 billion in wages nationwide from 2019 to 2024. That includes major construction projects in Indiana, helping grow middle-class careers and drive life sciences innovation.

The Institute for Construction Employment Research (ICERES) is a non-profit network of academic faculty and other scholars across the United States and Canada interested in conducting, collaborating on, and facilitating academic-quality research on construction labor issues. ICERES is committed to b...

07/01/2025

In a new opinion piece, PhRMA CEO Stephen J. Ubl outlines a better path to lowering prescription drug costs:
- Focus on the real drivers of cost like pharmacy benefit managers and hospitals that profit from the 340B program
- Ensure patients benefit from the discounts middlemen receive
- Require transparency and accountability
- Make sure other wealthy nations stop free-riding on American innovation

This is how we lower costs without sacrificing the research that brings new cures to patients.

Policymakers will need to address the true drivers of high drug prices here at home, while simultaneously pressing our allies to contribute more abroad, writes PhRMA’s Steve Ubl.